Table 4 Pharmacokinetic variables for belinostat (mean±s.d. for a single i.v. dose on days 1 and 3)

From: A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

Belinostat dose (mg m−2)

No. of patients

T 1/2 (h)

Cmax (μ M)

AUCall (h  μ M)

AUCinf (h  μ M)

Cl (l h−1 m−2)

Vss (l m−2)

600

12

1.7±0.9

58.5±13.8

28.4±7.1

28.4±7.1

69.7±15.2

34.9±6.4

800

4

1.7±0.2

70.8±18.9

35.5±8.7

35.6±8.7

73.7±14.1

38.1±9.7

1000 day 1

7

1.0±0.1

127.6±43.5

101.9±58.2

102.0±58.3

41.1±22.2

22.6±9.7

1000 day 3

7

2.7±0.4

134.7±54.9

88.8±63.9

88.8±63.9

45.1±17.3

35.8±17.3

  1. Abbreviations: AUC=area under curve; Cl=clearance; i.v.=intravenous; Vss=steady state volumes of distribution.
Back to article page